Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonidegib + gemcitabine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sonidegib (LDE225) is a small molecule inhibitor of the Hedgehog signaling pathway that acts by selectively inhibiting Smoothened (SMO), a key transmembrane protein in the pathway. It is developed for targeting tumor stroma and has been studied in combination with the chemotherapy agent gemcitabine for advanced and metastatic pancreatic ductal adenocarcinoma (PDAC). Gemcitabine is a nucleoside analog used as chemotherapy. The combination aims to disrupt tumor-stromal interactions and inhibit cancer cell proliferation by blocking aberrant Hedgehog signaling while simultaneously exerting cytotoxic effects through DNA synthesis inhibition[1][2][5][6]. Sonidegib was developed by Novartis.
- Brand names
- Odomzo
- Other names
- LDE225 + gemcitabineOdomzo + gemcitabine
02
Targets
DNA polymerase familySMO (Smoothened)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on sonidegib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonidegib + gemcitabine.